1型糖尿病治療薬市場：形態別、エンドユーザー別-2025-2030年の世界予測

1型糖尿病治療薬市場は、2023年に175億7,000万米ドルと評価され、2024年には191億4,000万米ドルに達すると予測され、CAGR 9.06%で成長し、2030年には322億4,000万米ドルに達すると予測されています。

1型糖尿病治療薬市場の特徴は、膵臓からのインスリン分泌がほとんどない、あるいは全くない慢性疾患である1型糖尿病の管理に不可欠なインスリンと関連医薬品に対する世界の需要です。1型糖尿病は、適切な治療を行わないと心血管疾患や神経障害などの深刻な合併症を引き起こす可能性があるため、血糖値を維持するための効果的な薬剤が急務となっています。1型糖尿病治療薬の用途は、患者個人の使用にとどまらず、糖尿病治療に重点を置く病院、診療所、研究機関などにも広がっています。新規診断例の大半は小児と若年成人であるため、最終使用例は小児と若年成人が中心です。

市場成長の主な要因は、世界の糖尿病有病率の増加、医療技術の進歩、糖尿病管理に関する意識の高まりです。次世代インスリン製剤や経口インスリン製剤などのバイオテクノロジーの革新は、市場プレーヤーにポートフォリオを拡大する大きな機会を提供しています。さらに、治療の有効性と患者のコンプライアンスを高めるために、個別化医療のアプローチや、スマートインスリンペンや持続グルコースモニターなどのデジタルヘルスソリューションの開発が重視されるようになっています。しかし、厳しい規制の枠組み、高い開発コスト、医薬品の潜在的な副作用など、成長を阻害しかねない課題も残っています。さらに、ヘルスケアへのアクセスや経済的な余裕に格差があるため、新興国市場における市場開拓は依然として限定的です。

イノベーションと研究に最適な分野は、クローズドループインスリンデリバリーシステムの開発と、インスリンの必要性をより正確に予測するためのAI技術と糖尿病管理ツールの組み合わせにあります。これらの分野への投資は、糖尿病治療をさらに合理化し、患者のQOLを高め、最終的にはヘルスケアコストを削減する可能性があります。企業が規制上のハードルを乗り越え、技術的進歩を活用して1型糖尿病患者の進化するニーズに応えることができれば、市場は依然として非常にダイナミックであり、かなりの成長の可能性を秘めています。

市場力学：急速に進化する1型糖尿病治療薬市場の主要市場インサイトを公開

1型糖尿病治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の1型糖尿病の増加
  • 可処分所得の増加に伴うヘルスケア支出の増加
  • 1型糖尿病治療に対する患者の意識の高まり
• 市場抑制要因
  • 医薬品の特許切れ
• 市場機会
  • 新規糖尿病治療薬のイントロダクションの台頭
  • 1型糖尿病治療薬の研究開発の急増
• 市場の課題
  • 医薬品の承認に関する厳しい規制

ポーターの5つの力：1型糖尿病治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：1型糖尿病治療薬市場における外部からの影響の把握

外部マクロ環境要因は、1型糖尿病治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析1型糖尿病治療薬市場における競合情勢の把握

1型糖尿病治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス1型糖尿病治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、1型糖尿病治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨1型糖尿病治療薬市場における成功への道筋を描く

1型糖尿病治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 1型糖尿病の発症が世界中で増加
    • 可処分所得の増加に伴うヘルスケア費の増加
    • 1型糖尿病治療に対する患者の意識の高まり
  • 抑制要因
    • 医薬品の特許切れ
  • 機会
    • 糖尿病治療のための新薬のイントロダクション
    • 1型糖尿病治療薬の研究開発活動の急増
  • 課題
    • 承認薬に対する厳しい規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 1型糖尿病治療薬市場：形態別

• インスリン療法
  • 持続性インスリン
  • プレミックスアナログ
  • 速効性インスリン
• 経口薬
  • ビグアナイド
    • メトホルミン
    • メトホルミン徐放性
  • ナトリウムグルコース共輸送体2（SGLT2）阻害剤
    • カナグリホジン
    • ダパグリフロジン
    • エンパグリフロジン
    • エルツグリフロジン

第7章 1型糖尿病治療薬市場：エンドユーザー別

• 薬局
• 病院

第8章 南北アメリカの1型糖尿病治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の1型糖尿病治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの1型糖尿病治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• AstraZeneca PLC
• B. Braun Melsungen AG
• Biocon Limited
• DAIICHI SANKYO COMPANY, LIMITED
• Eli Lilly and Company
• GSK plc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• XOMA Corporation

LIST OF FIGURES

• FIGURE 1. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
• FIGURE 2. TYPE 1 DIABETES DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TYPE 1 DIABETES DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 48. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 51. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 52. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 80. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 82. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 83. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 84. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 86. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 87. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 88. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 89. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 90. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 152. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 189. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 190. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 191. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 192. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 193. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 213. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 214. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 215. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 216. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 217. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 219. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 220. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 221. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 222. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 223. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 224. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 254. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 260. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 266. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 279. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Type 1 Diabetes Drug Market was valued at USD 17.57 billion in 2023, expected to reach USD 19.14 billion in 2024, and is projected to grow at a CAGR of 9.06%, to USD 32.24 billion by 2030.

The Type 1 Diabetes Drug market is characterized by the global demand for insulin and related medications essential for managing Type 1 Diabetes, a chronic condition where the pancreas produces little or no insulin. As Type 1 Diabetes can lead to serious complications like cardiovascular disease and nerve damage if untreated properly, there is a pressing necessity for effective medications to maintain blood sugar levels. Application of Type 1 Diabetes drugs extends beyond personal patient use to include hospitals, clinics, and research institutions focused on diabetes treatment. The end-use scope predominantly consists of children and young adults, as this demographic represents the majority of new diagnosis cases.

Market growth is primarily fueled by increasing prevalence rates of diabetes globally, advancements in medical technology, and heightened awareness regarding diabetes management. Biotechnological innovations, such as next-generation insulin products and oral insulin, offer substantial opportunities for market players to expand their portfolios. Additionally, there is a growing emphasis on developing personalized medicine approaches and digital health solutions, such as smart insulin pens and continuous glucose monitors, to enhance treatment efficacy and patient compliance. However, challenges persist, including stringent regulatory frameworks, high development costs, and the potential side effects of drugs, which can impede growth. Moreover, disparities in healthcare access and affordability continue to limit market reach in developing regions.

The best areas for innovation and research lie in the development of closed-loop insulin delivery systems and combining AI technology with diabetes management tools to predict insulin needs more accurately. Investments in these areas could further streamline diabetes care, enhance patient quality of life, and ultimately reduce healthcare costs. The market remains highly dynamic, with considerable potential for growth, provided companies can navigate regulatory hurdles and leverage technological advancements to meet the evolving needs of patients with Type 1 Diabetes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidences of type 1 diabetes globally
  • Increasing healthcare expenditure with rising disposable income
  • Rising patient awareness on type 1 diabetes treatment
• Market Restraints
  • Patent expiration of drugs
• Market Opportunities
  • Emerging introduction of novel drugs to treat diabetes
  • Surge in research and development activities for type 1 anti-diabetic drugs
• Market Challenges
  • Strict regulations for the approval drugs

Porter's Five Forces: A Strategic Tool for Navigating the Type 1 Diabetes Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Type 1 Diabetes Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Type 1 Diabetes Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Type 1 Diabetes Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Type 1 Diabetes Drug Market

A detailed market share analysis in the Type 1 Diabetes Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Type 1 Diabetes Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Type 1 Diabetes Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Type 1 Diabetes Drug Market

A strategic analysis of the Type 1 Diabetes Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Type 1 Diabetes Drug Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, B. Braun Melsungen AG, Biocon Limited, DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

Market Segmentation & Coverage

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Form, market is studied across Insulin Therapy and Oral Medication. The Insulin Therapy is further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication is further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. The Biguanides is further studied across Metformine and Metformine Extended-Release. The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors is further studied across Canaglifozine, Dapagliflozine, Empagliflozine, and Ertugliflozine.
• Based on End User, market is studied across Drugstore and Hospital.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of type 1 diabetes globally
    • 5.1.1.2. Increasing healthcare expenditure with rising disposable income
    • 5.1.1.3. Rising patient awareness on type 1 diabetes treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Patent expiration of drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging introduction of novel drugs to treat diabetes
    • 5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulations for the approval drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Type 1 Diabetes Drug Market, by Form

• 6.1. Introduction
• 6.2. Insulin Therapy
  • 6.2.1. Long-Acting Insulin
  • 6.2.2. Premix Analogs
  • 6.2.3. Rapid Acting Insulin
• 6.3. Oral Medication
  • 6.3.1. Biguanides
    • 6.3.1.1. Metformine
    • 6.3.1.2. Metformine Extended-Release
  • 6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
    • 6.3.2.1. Canaglifozine
    • 6.3.2.2. Dapagliflozine
    • 6.3.2.3. Empagliflozine
    • 6.3.2.4. Ertugliflozine

7. Type 1 Diabetes Drug Market, by End User

• 7.1. Introduction
• 7.2. Drugstore
• 7.3. Hospital

8. Americas Type 1 Diabetes Drug Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Type 1 Diabetes Drug Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Type 1 Diabetes Drug Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. AstraZeneca PLC
• 3. B. Braun Melsungen AG
• 4. Biocon Limited
• 5. DAIICHI SANKYO COMPANY, LIMITED
• 6. Eli Lilly and Company
• 7. GSK plc
• 8. Johnson & Johnson Services, Inc.
• 9. Novartis AG
• 10. Novo Nordisk A/S
• 11. Pfizer Inc.
• 12. Samsung Bioepis Co., Ltd.
• 13. Sanofi S.A.
• 14. Teva Pharmaceutical Industries Ltd.
• 15. XOMA Corporation